Clinical significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in pleural effusion

doi:10.3877/cma.j.issn.1674-0785.2017.14.002

Abstract

Abstract:

Objective

To assess the significance of COX-2 and VEGF in the differential diagnosis of benign and malignant pleural effusions by detecting their levels in pleural effusion.

Methods

Fifty-eight cases of pleural effusion were collected at our hospital, including 48 cases of malignant pleural effusion and 10 cases of benign pleural effusion. Expression levels of COX-2 and VEGF in pleural effusions were detected by ELISA and compared between benign and malignant pleural effusions.

Results

The expression levels of COX-2 and VEGF had no significant association with gender or age in both 48 cases of malignant pleural effusion and 10 cases of benign pleural effusion (P>0.05). The average COX-2 and VEGF levels were (788.04 ± 128.85) U/L and (365.27 ± 80.63) ng/L, respectively, in the malignant pleural effusion group, and the corresponding values in the benign pleural effusion group were (366.92 ± 41.08) U/L and (114.67 ± 15.69) ng/L. COX-2 and VEGF levels in malignant pleural effusion were significantly higher than those in benign pleural effusion (P<0.001).

Conclusion

COX-2 and VEGF expression levels are higher in malignant pleural effusion than in benign pleural effusion, and they may serve as prognostic factors to distinguish between benign and malignant pleural effusions.

Key words: Cyclooxygenase-2, Vascular endothelial growth factor, Pleural effusion, Tumor

Fangzheng Zhao, Xinhua Zheng, Chuanjun Huang, Penghui Deng, Xiaodan Gong, Caiqing Zhang. Clinical significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in pleural effusion[J]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(14): 2019-2022.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2017.14.002

https://zhlcyszz.cma-cmc.com.cn/EN/Y2017/V11/I14/2019

Figures/Tables 2

References 18

[1]	阮光强，王羡强，陈国军, 等. 胸水中VEGF、TNF-α的检测对良恶性胸水的鉴别诊断意义 [J]. 现代生物医学进展, 2012, 12(15):2952-2953,2958.
[2]	Antonangelo L, Sales RK, Corá AP, et al. Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results [J]. Curr Oncol, 2015, 22(5):336-341.
[3]	Cheng F, Wang Q, Zhong D. Value of cell block in the diagnosis of malignant pleural effusion [J]. Zhongguo Fei Ai Za Zhi, 2015, 18(10):652-655.
[4]	Wasilewicz MP, Kołodziej B, Bojułko T, et al. Expression of cyclooxygenase-2 in colonic polyps [J]. Pol Arch Med Wewn, 2010, 120(9):313-320.
[5]	Fiorelli A, Vicidomini G, Di Domenico M, et al. Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications [J]. Interact Cardiovasc Thorac Surg, 2011, 12(3):420-424.
[6]	徐杰，齐大亮，李绪斌, 等. 重组人血管内皮抑制素联合化疗治疗非小细胞肺癌恶性胸腔积液的疗效观察 [J]. 中国肿瘤临床, 2014, 41(24):1573-1576.
[7]	Hooper C, Lee YC, Maskell N. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010 [J]. Thorax, 2010, 65(2):4-17.
[8]	Qu L, Liu B. Cyclooxygeanse-2 promotes metastasis in osteosarcoma [J]. Cancer Cell Int, 2015, 15(1):69-75.
[9]	Singh-Ranger G, Giordano P. A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer [J]. Int J Colorectal Dis, 2009, 24(7):863.
[10]	Lobo PK, Vu L, Chan SK, et al. Predictive utility of cyclooxygenase-2 expression by colon and rectal cancer [J]. Am J Surg, 2014, 207(5):712-716.
[11]	Gou HF, Chen XC, Zhu J, et al. Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications [J]. J Exp Clin Cancer Res, 2011, 30(9):14-18.
[12]	Elzagheid A, Emaetig F, Alkikhia L, et al. High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer [J]. Anticancer Res, 2013, 33(8):3137-3143.
[13]	Weidner N. Introtumor microvessel density as a prognostic factor in cancer [J]. Am J Pathol, 1995, 147(1):9-19.
[14]	Alevizakos M, Kaltsas S, Syrigos KN. The VEGF pathway in lung cancer [J]. Cancer Chemother Pharmacol, 2013, 72(6):1169-1181.
[15]	Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor(vascular endothelial growth factor)and its receptors in adenocarcinomas of the gastrointestinal tract [J]. Cancer Res, 1993, 53(19):4727-4735.
[16]	Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation [J]. Clin Cancer Res, 2000, 6(3):957-965.
[17]	Christoph B. Transforming growth factor-β1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular cancer cell [J]. Cancer Res, 2003, 63(5):1083-1092.
[18]	Yuan A, Yu CJ, Shun CT, et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients [J]. Int J Cancer, 2005, 115(4):545-555.

组别	例数	COX-2（U/L）	VEGF（?ng?/L）
试验组	48	788.04±128.85	365.27±80.63
对照组	10	366.92±41.08	114.67±15.69
P值	?	＜0.05	＜0.05

组别	例数	COX-2（U/L）	VEGF（?ng?/L）
试验组	48	788.04±128.85	365.27±80.63
对照组	10	366.92±41.08	114.67±15.69
P值	?	＜0.05	＜0.05

肿瘤类型	例数	COX-2（U/L）	VEGF（?ng?/L）	r值	P值
肺癌	23	847.21±131.89^a	403.12±89.23^a	0.89	＜0.05
乳腺癌	11	759.35±97.16^a	330.22±38.57^a	0.78	＜0.05
肝癌	6	710.33±95.38^a	307.05±57.93^a	0.91	＜0.05
胃癌	8	676.89±62.74^a	365.98±39.12^a	0.77	＜0.05
结核性胸膜炎	10	368.52±39.97	115.03±16.25	?	?

肿瘤类型	例数	COX-2（U/L）	VEGF（?ng?/L）	r值	P值
肺癌	23	847.21±131.89^a	403.12±89.23^a	0.89	＜0.05
乳腺癌	11	759.35±97.16^a	330.22±38.57^a	0.78	＜0.05
肝癌	6	710.33±95.38^a	307.05±57.93^a	0.91	＜0.05
胃癌	8	676.89±62.74^a	365.98±39.12^a	0.77	＜0.05
结核性胸膜炎	10	368.52±39.97	115.03±16.25	?	?

Please choose a citation manager

Content to export